

ANTICANCER POTENTIAL OF *RHYCHOSIA BEDDOMEI*: AN *IN VITRO* AND *IN SILICO* STUDY

ABSTRACT

Rhychosia beddomei is widely distributed in tropical and subtropical regions around the world. Traditionally this plant has been used as a medicine for multiple ailments including cancer. The present study addresses the evaluation of *in vitro* anticancer activity by using MTT Assay of methanolic extracts of whole plant of *Rhychosia beddomei* in Human Hepatocellular Carcinoma (HepG2) cell line in comparison with standard drug doxorubicin as well as *in silico* analysis. Doxorubicin acts in the cancer cell by intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair and generation of free radicals and their damage to cellular membranes, DNA and proteins. Cytotoxicity studies have indicated that the phytoconstituents of *Rhychosia beddomei* have the ability to selectively target cancer, whereas minimal or negligible cytotoxic effects were observed on normal cells. The molecular docking approach was employed to check binding conformations of phytochemicals against human cyclin-dependent kinase 2, CDK-2 and Topoisomerase-2, Topo-II proteins (Protein Data bank-ID: 1DI8 and 1ZXM) through Molecule online molecular modelling tool. The docking revealed an encouraging binding score with a maximum score of -11.5 and -10.4 kCal/mol with CDK-2 and Topo-II respectively and all the selected ligands indicate promising anticancer activity. Molecular docking studies using the phytoconstituents were performed in order to gain a better understanding of the putative mechanisms of action leading to the development of improved and affordable therapies. This study paves a way to better understand the integration of molecular docking and *in vitro* studies can accelerate cancer drug discovery showing a good consistency of anticancer therapeutic drug potentials of *Rhychosia beddomei* by *in vitro* and *in silico* approaches.

Keywords: *Rhychosia beddomei*, Molecular docking, MTT assay, HepG2 cell lines.

1. Introduction

“Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the two major forms of primary liver cancers (PLC), accounting for approximately 90% and 5% respectively” [1, 2]. “The incidence of each is the most common widespread cancer in the world. HCC causes high annual mortality rates, particularly in Thailand, Cambodia and Laos, where viral hepatitis is endemic” [3]. “The induction of HCC is preceded by the occurrence of hepatocellular damage via reactive oxygen species (ROS) and the generation of chronic inflammation related to hepatocarcinogenesis” [4]. “Adjunctive therapies such as tumor necrosis factor and melphalan; or cisplatin, epirubicin and 5-FU; doxorubicin, interferon alpha and 5-FU have been used to overcome the HCC” [5]. “However, the main problem of chemotherapy to treat HCC is the cancer resistance mechanism, due to up-regulation of the multi-drug resistance protein (MDR) and a decrease of apoptotic proteins” [6]. “Thus, more effective chemotherapy is needed to control cancer and apoptosis induction, which is the desired effect for successful cancer treatment” [7].

Rhynchosia beddomei. (*Papilionaceae*) is rare medicinal plant found in the Eastern Ghats of Andhra Pradesh. Locally, it is known as adavi kandi and vendaku. The plant parts were used in traditional medicine to cure various diseases viz., leaves for abortifacient, antibacterial, antifungal, antidiabetic [8], hepatoprotective properties [9] and also used for healing wounds, cuts, boils and rheumatic pains. The anti-cancer activity of methanolic extract of *Rhynchosia beddomei* (*Papilionaceae*) (MERB) whole plant against MTT assay and *in silico* docking studies of isolated compounds from the plant have not been reported so far scientifically. Hence, the present study has been carried out to evaluate the anti-cancer activity of MERB.

2. Materials and Methods

2.1 Plant materials

Rhynchosia beddomei Baker whole plant was collected in the month of November 2014 from Sheshachalam hills, Tirupati, Andhra Pradesh, India. The plant was then taxonomically identified and authenticated by the botanist Dr. K. Madhava Chetty, Assistant Professor in S.V. University, Tirupati, India.

2.2 Preparation of extract

“The plant was dried under shade then coarsely powdered with a mechanical grinder. The powder was passed through a sieve and stored in an airtight container for the extraction, and extracted with methanol 70% (75-78°C) up to 72 hrs, as the yield was more for methanol in the selected solvents. After completion of extraction, the solvent was removed by distillation.

Dark brown residue was obtained. The residue was concentrated and then stored in desiccators” [10].

2.3 Preliminary Phytochemical Investigation

The extract was were subjected to various preliminary phytochemical tests to detect the phytoconstituents present in the plant extract [11].

2.4 Method

The *in vitro* MTT assay was performed for the test substances on HepG2 (Human Hepatocellular Carcinoma) cell line to determine the level of cytotoxicity.

2.5 Preparation of test compound for Cytotoxicity screening

10 mg of test substances was weighed and dissolved in DMEM-HG medium supplemented with 2% inactivated FBS to obtain a stock solution of 10 mg/mL. Furthermore, serial two-fold dilutions were prepared from the stock solution to prepare lower concentrations for cytotoxicity testing [12].

2.6 Cell line and culture medium

Human Hepatocellular Carcinoma cell line cell line was procured from National Centre for Cell Sciences (NCCS), Pune. Stock cells were cultured in DMEM-HG supplemented with 10% inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), streptomycin (100 µg/mL) and amphotericin B (5 µg/ml) in a humidified atmosphere of 5% CO₂ at 37°C until confluent. The cells were dissociated with TPVG solution (0.2% Trypsin, 0.02% EDTA, 0.05% glucose in PBS). The stock cultures were grown in 25 cm² culture flasks and all experiments were carried out in 96 well microtitre plates (Tarsons India Pvt. Ltd., Kolkata, India).

2.7 Determination of Cell viability by MTT Assay

The monolayer cell culture was trypsinized and the cell count was adjusted to 100,000 cells/ml using DMEM-HG containing 10% FBS. To each well of the 96 well microtitre plate, 0.1 mL of the diluted cell suspension was added. After 24 h, when a partial monolayer was formed, the supernatant was flicked off, the monolayer washed once with medium and different test concentrations were added on to the partial monolayer in the microtitre plates. The untreated cells were maintained as cell control for comparison. The plates were then incubated at 37°C for 24 h in 5% CO₂ atmosphere, and microscopic examination was carried out and observations were noted after 24h, the test solutions in the wells were discarded and 50 µL of MTT is added with DPBS was added to each well. The plates were gently shaken and incubated for 3 h at 37 °C in 5% CO₂ atmosphere. The supernatant was removed and 100

μ L of Isopropanol was added and the plates were gently shaken to solubilize the formed formazan. The absorbance was measured using a microplate reader at a wavelength of 570 nm.

2.8 Molecular Docking Studies

Initially the proteins were downloaded from PDB was prepared by removing extra chains. Attributes of spheres are prepared and noted. Later molecules drawn in molecular and ligand preparation was created. Proteins are uploaded with sphere attributes and the structures were docked against 1DI8 and 1ZXM proteins. Docking indicated that some of our compounds have good binding ability with both CDK-2 and Topo-II proteins. Following are the ligand interactions of compounds present in *Rhychosia beddomei* whole plant with 1DI8 and 1ZXM proteins [13].

2.8.1 Protein-ligand interactions

Docking stimulations predicts the binding orientation of drug candidates to their protein targets. Mcule was used for generating docking simulation studies.

2.8.2 Docking simulations on Cyclin-dependent kinase-2 (1DI8), Human topoisomerase II (1ZXM)

“Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S- and M-phases of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is critically associated with tumor growth in multiple cancer types. Selective CDK2 inhibition may provide a therapeutic benefit against certain tumors, and it continues to appeal as a strategy to exploit in anticancer drug development” [14]. DNA topoisomerases are nuclear enzymes that catalyze the introduction of topological changes to the DNA molecule. Replication and transcription of DNA require the unwinding of the DNA helix, which results in helical tension in the rest of the DNA molecule. Topoisomerases release this tension through the formation of transient single-stranded (i.e., type I topoisomerases) or double-stranded (i.e., type II topoisomerases) breaks in the DNA double helix, which makes topoisomerases essential for proliferating cells.

Hence, we report the molecular docking analysis of CDK 2 and Topo II with phytocompounds.

2.8.3 Ligand preparation

The 2D ligands sketched in Mcule docking in the ligand imported side.

2.8.4 Protein preparation

The x-ray crystallised structure of Cyclin-dependent kinase-2 (PDB ID: 1DI8) and Human topoisomerase II protein (PDB ID: 1ZXM) were retrieved from RCSB protein bank. Attributes of SBD site sphere are obtained from discovery studio visualizer.

2.8.5 Ligand docking and scoring

Protein ligand interactions were stimulated through flexible glide-ligand docking with mCULE Docking allowed. The compounds docked displays a docking score

2.8.6 Visualization and analysis

The resulting docking poses were visualized through discovery studio visualizer. The ligand interactions were visualized to know the binding interactions between ligands and protein. The best docked structures were chosen using glide score function. The more negative the score the more favourable the binding. Additionally, the docked ligand poses were visualized and the different ligand receptor interactions were studied.

3. Results and Discussion

The plant was collected, authenticated and extracts were prepared using solvents like methanol and the yield of methanolic extract was found to be 63% respectively.

3.1 Preliminary Phytochemical analysis

The preliminary phytochemical investigation of methanolic extract of whole plant of *Rhynchosia beddomei* showed the presence of alkaloids, glycosides, carbohydrates, tannins are present in minor quantities. Flavonoids, steroids are present in major quantities. The results are showed in Table 1.

Table 1 Preliminary Phytochemical analysis

Phytoconstituents	Results
Alkaloids	+
Glycosides	+
Steroids	++
Flavonoids	++
Carbohydrates	+
Proteins	-

Tannins	+
Volatile oil	-

Note: + indicates present; - indicates absent.

3.2 *In vitro* MTT assay

“The results revealed that the cytotoxicity rate was increased when the concentrations of leaf extract increases. MTT assay measured the cell viability based on the reduction of yellow tetrazolium MTT to a purple formazan dye mitochondrial dehydrogenase enzyme. So, the amount of formazan produced reflected the number of metabolically active viable cells” [15]. The CTC₅₀ values observed for Cell line HepG2 against methanolic extract of *Rhynchosia beddomei* was 245.1µg/ml given in table 2. Test substances were assayed for *in vitro* cytotoxicity study against HepG2 cells (Human Hepatocellular carcinoma) by exposing the cells to different concentrations ranging from 8 to 1000 µg/mL. MTT assay was employed to test the cytotoxic effect of selected concentrations of the plant extract on the cell viability of HepG2 cells by measuring the metabolic activity through a colorimetric determination. Cell viability is a measure of the proportion of live, healthy cells within a population. The MTT assay is usually carried out to detect the cells with constant mitochondrial activity, thereby; an increase or decrease in the number of viable cells is linearly related to mitochondrial activity. In the present study, the CTC₅₀ value of the plant extract was found to be 245.1µg/mL. The plant extract exhibited 75.68±1.44% toxicity in HepG2 cells at the highest concentration tested (1000 µg/mL) and the CTC₅₀ value of the Doxorubicin was found to be 0.485 µg/mL given in table 3.

“The plant has the enormous medicinal properties and its various parts used to cure many diseases. Quercetin exhibits direct proapoptotic effects on tumor cells and thus can inhibit the progress of numerous human cancers. The anticancer effect of quercetin has been documented in numerous *in vitro* and *in vivo* studies that involved several cell lines and animal models. On the other hand, the high toxic effect of quercetin against cancer cells is accompanied with little or no side effects or harm to normal cells” [16]. “Recently, apigenin has been widely investigated for its anti-cancer activities and low toxicity. Apigenin was reported to suppress various human cancers *in vitro* and *in vivo* by multiple biological effects, such as triggering cell apoptosis and autophagy, inducing cell cycle arrest, suppressing cell migration and invasion, and stimulating an immune response” [17].

“The naturally occurring flavonoids are reported to possess multiple biological activities” [18, 19]. “Flavonoids have been shown to possess a wide variety of anticancer effects: they

modulate reactive oxygen species (ROS)-scavenging enzyme activities, participate in arresting the cell cycle, induce apoptosis, autophagy, and suppress cancer cell proliferation and invasiveness. Multiple studies report flavonoids to cause inhibition of the growth factor receptors. and/or multiple downstream signalling pathways, inhibition of activation of carcinogens and inhibition of cyclin-dependent kinases. Among flavonoids, rutin is a common dietary flavonoid that has been found in numerous foods, beverages, and vegetables. Various effects of rutin, including antimicrobial, antidiabetic, antioxidant, anti-inflammatory, anticancer, and neuroprotection effects, have been shown in several studies” [20]. “Also, many studies indicated that it could act as a chemopreventive and chemotherapeutic agent. Its antitumor products are via the suppression of cell proliferation, the induction of autophagy or Apoptosis, and the prevention of metastasis and angiogenesis. In many human cancer cell lines, rutin has caused cell cycle arrest and apoptosis” [21]. Since the presence of flavonoids in the extract might be responsible for the anticancer activity.

Table 2: MTT Assay- Percentage cytotoxicity of MERB against Hep G2 cell lines

Test substance	Concentration (µg/mL)	Percentage Cytotoxicity	CTC ₅₀ (µg/mL)
Methanolic extract of <i>Rhynchosia beddomei</i>	1000	75.68±1.44	245.1
	500	67.54±0.44	
	250	58.22±0.58	
	125	5.65±0.18	
	62.5	3.82±0.07	
	31.25	2.91±0.79	
	15.625	1.60±0.57	
	7.8	0.55±0.57	

Table 3: *In vitro* MTT assay –Percentage cytotoxicity of Doxorubicin against HepG2 cell lines

μM of Doxorubicin	μg of Doxorubicin	Cytotoxicity %	CTC ₅₀ ($\mu\text{g}/\text{mL}$)
10	5	86.28	
5	2.5	84.79	
1	1.25	70.17	
0.5	0.625	57.47	0.485
0.25	0.312	41.63	
0.125	0.156	35.76	
0.0625	0.078	28.59	

Table 4: Molecular docking studies of isolated compounds against Topoisomerase-2 and CDK-2

Compounds	Cyclin Dependent Kinase II (1DI8)	Topoisomerase II (1ZXM)
	Docking Score	Docking Score
Quercetin-7-O-methyl ether	-9.3	-9.7
Isovitexin	-9.7	-7.8
5,7,3',4'-tetrahydroxy 6-c- β -D-glucopyrynosyl flavone	-9.6	-10.2
Apigenin	-9.8	-9.3
Vitexin	10.9	-9.3
Vicenin	-11.1	-5.4

Orientin	-10.9	-9.8
Isoorientin	-10.7	-8.8
Lucenin	-11.5	-5.5
Rutin	-9.3	-10.4
Rhynchosin	-9.7	-10.0
Biochanin	-8.8	-9.2

3.3 Molecular Docking Studies

Initially the proteins were downloaded from PDB was prepared by removing extra chains. Attributes of spheres are prepared and noted. Later molecules drawn in molecular and ligand preparation was created. Proteins are uploaded with sphere attributes and the structures were docked against 1DI8 and 1ZXM proteins. Docking indicated that some of our compounds have good binding ability with both Cyclin-dependent kinase-2 and Human topoisomerase II proteins represented in table 4. Following are the ligand interactions of compounds present in *Rhychosia beddomei* whole plant with 1DI8 and 1ZXM proteins represented in figure 1 and 2.




Figure 1: Docking poses of phytocompounds with Cyclin-dependent kinase-2




Figure 2: Docking poses of phytochemicals with Human topoisomerase II protein

The molecular docking in this study shows a vital role in predicting molecular interactions of phytochemicals with targeted proteins. This application is widely used in the pharmaceutical industry as a powerful tool, particularly in the analysis of structure–activity relationship. The analysis of molecular docking outputs, such as binding affinity, are frequently applied in the determination of potential ligands. Molecular docking also has the ability to predict small molecule ligands binding toward appropriate target binding site.

Lucinen, vicenin and orientin have demonstrated remarkable binding affinity towards Cyclin-dependent kinase-2. Lucinen shown highest docking score -11.5 in comparison to other compound towards CDK-2 [22]. Rutin, 5,7,3',4'-tetrahydroxy 6-c-β-D-glucopyrynosyl flavone and Rhynchosin have demonstrated remarkable binding affinity towards Topo II. Rutin shown highest docking score -10.4 in comparison to another

compound. Thus, indicating that these compounds are potent inhibitor of the CDK-2 antiapoptotic family of proteins and TOPO-2 proteins [23].

The application of molecular docking studies for the compounds that are present in methanolic extract of *Rhynchosia beddomei* with proteins 1DI8 and 1ZXM are considered very useful and proven anticancer activity. Our findings conclude that all phytocompounds are possibly able to act as potential inhibitors for the targeted 1DI8 and 1ZXM proteins, supported by the high binding affinities.

4. Conclusion

The present study scientifically established the *in vitro* MTT assay and *in silico* docking studies to predict anticancer activity. The MTT assay was performed and the results showed that the extract has anticancer activity. From docking scores, we can conclude that the isolated compounds from the extract possess anticancer activity through inhibition of CDK-2 and Topo-II can be further preceded to wet lab synthesis.

REFERENCES

1. Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: One step closer to personalized medicine? Cell Biosci. 2011;1:5.
2. Sithithaworn P, Haswell-Elkins M. Epidemiology of *Opisthorchis viverrini*. Acta Tropica. 2003;88:187–194.
3. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol. 2008;48:858–879.
4. Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y, Iwasa M, Ma N, Kawanishi S, Watanabe S, Kaito M and Takei Y. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer. 2008;98:580–586.
5. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 2006;5:1–6.

6. Chen YB, Yan ML, Gong JP, Xia RP, Liu LX, Lu SC, Zeng JG, Xie DB, Yang JG, Yan JY. Establishment of hepatocellular carcinoma multidrug resistant monoclonal cell line HepG2/mdr1. *Chinese Med J (Engl)*. 2007;120:703–707.
7. Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, Zitvogel L. Desirable cell death during anticancer chemotherapy. *Ann N Y Acad Sci*. 2010;1209:99-108.
8. Suvarchala Reddy NVL, Mary JL, Raghavendra NM, Subrahmanyam CVS. Antidiabetic and Antioxidant Activity of *Rhynchosia beddomei* Baker. *American Journal of Phytomedicine and Clinical Therapeutics*. 2014;2: 1323-1332.
9. Suvarchala Reddy NVL, Maleka Anjum, Swetha Aveti, Ganga Raju M. Hepatoprotective Activity of Methanolic Extract of Whole Plant of *Rhynchosia beddomei* in Wistar Rats. *J Pharm Chem Biol Sci* 2015; 3(3): 378-387.
10. Suvarchala Reddy VNVL, Anarthe SJ, Subrahmanyam CVS, Raghavendra NM. Antihypertensive, ACE Inhibitory and Antioxidant Activity of Whole Plant of *Rhynchosia beddomei*. *Asian Journal of Pharmacology and Toxicology*. 2015;03(10): 13-18.
11. Suvarchala Reddy NVL, Ganga Raju M, Shabnam kumari T, Mamatha M. Evaluation of Ethanolic Extract of *Millingtonia hortensis* leaves by Streptozotocin Induced Diabetic Nephropathy and Diuretic Activity in Wistar Rats. *Adv Biores*. 2021; 12 (3): 42-48.
12. Francis D and Rita L. Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. *Journal of Immunological Methods*, 1986; 89: 271-277.
13. Ikwu FA, Isyaku Y, Obadawo BS, Lawal HA, Ajibowu SA. *In silico* design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell line. *J Genet Eng Biotechnol* 2020;18:51.
14. Suvarchala Reddy NVL, Akhila M, Subrahmanyam CVS, Trimurtulu G, Raghavendra NM. Isolation, *in vitro* antidiabetic, antioxidant activity and molecular docking studies of pentacyclic triterpenoids from *Syzygium alternifolium* (wt.) Walp bark. *IOSR Journal of Pharmacy and Biological Sciences*. 2015;10(6): 148-154.
15. Satish BN, Mallya SV, Vishwanatha. Screening for cytotoxic activity of *Habenaria longicorniculata* J graham tubers-an *in vitro* study. *J Phytopharmacol* 2020; 9(5):367-370.

16. Rauf A, Imran M, Khan IA, Ur-Rehman M, Gilani SA, Mehmood Z, Mubarak MS. Anticancer potential of quercetin: A comprehensive review. *Phytotherapy research*. 2018;32(11):2109–2130.
17. Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: Anti-cancer effects and mechanisms of action. *Cell & bioscience*, 2017;7:50.
18. Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as Anticancer Agents. *Nutrients*. 2020; 12(2):457.
19. Azhar U. Khan, Hanuman S. Dagur, Masudulla Khan, Nazia Malik, Mahboob Alam, Md Mushtaque. Therapeutic role of flavonoids and flavones in cancer prevention: Current trends and future perspectives. *European Journal of Medicinal Chemistry Reports*. 2021;3: 100010.
20. Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, Kandaswami C, Middleton Jr E, Lee MT. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. *British journal of pharmacology*. 1999;128(5):999-1010.
21. Perk AA, Shatynska-Mytsyk I, Gerçek YC, Boztaş K, Yazgan M, Fayyaz S, Farooqi AA. Rutin mediated targeting of signaling machinery in cancer cells. *Cancer Cell Int*. 2014 Nov 30;14(1):124.
22. Sumirtanurdin R, Sungkar S, Hisprastin Y, Sidharta KD, Nurhikmah DD. Molecular Docking Simulation Studies of Curcumin and Its Derivatives as Cyclin-Dependent Kinase 2 Inhibitors. *Turk J Pharm Sci*. 2020;17(4):417-423.
23. Nitis JL. DNA topoisomerase II and its growing repertoire of biological functions. *Nat. Rev. Cancer*. 2009;9(5): 327– 337.

UNDER PEER REVIEW